• Publications
  • Influence
Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
Atomoxetine (Strattera(R)) is a selective norepinephrine (noradrenaline) reuptake inhibitor that is not classified as a stimulant, and is indicated for use in patients with attention-deficitExpand
  • 170
  • 5
Panobinostat: First Global Approval
Novartis has developed oral and intravenous formulations of panobinostat (Farydak®), a histone deacetylase (HDAC) inhibitor, for the treatment of cancer. HDACs have important roles in maintainingExpand
  • 105
  • 5
Loxoprofen: A Review in Pain and Inflammation
Loxoprofen (Loxonin®, Loxonin® Pap, Loxonin® Tape) is a prodrug-type NSAID that is available in several formulations, including 60 mg tablets, 100 mg hydrogel patches and 50 or 100 mg tape. In activeExpand
  • 14
  • 5
Ripasudil: First Global Approval
Ripasudil hydrochloride hydrate (Glanatec® ophthalmic solution 0.4 %; hereafter referred to as ripasudil) is a small-molecule, Rho-associated kinase inhibitor developed by Kowa Company, Ltd. for theExpand
  • 108
  • 4
Esmolol: a review of its use in the short-term treatment of tachyarrhythmias and the short-term control of tachycardia and hypertension.
Supraventricular tachyarrhythmia (including atrial fibrillation), hypertension and tachycardia in the perioperative setting, and acute ischaemic heart disease are generally agreed to require rapidExpand
  • 31
  • 3
Brentuximab Vedotin: A Review of Its Use in Patients with Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma Following Previous Treatment Failure
Brentuximab vedotin (ADCETRIS®) is an antibody-drug conjugate that is specifically targeted against CD30-positive cancer cells such as those in Hodgkin lymphoma or systemic anaplastic large cellExpand
  • 23
  • 3
Brexpiprazole: A Review in Schizophrenia
Oral brexpiprazole (Rexulti®) is a partial dopamine D2 agonist, which also has activity at several other receptors. This article reviews the pharmacological properties of brexpiprazole and itsExpand
  • 19
  • 3
Secukinumab: A Review in Moderate to Severe Plaque Psoriasis
Secukinumab (Cosentyx™) is a fully human monoclonal immunoglobulin G1κ antibody targeting human interleukin-17A, an important cytokine in the pathogenesis of psoriasis. Secukinumab, as well as beingExpand
  • 32
  • 3
  • PDF
Oromucosal Midazolam: A Guide to Its Use in Paediatric Patients with Prolonged Acute Convulsive Seizures
Oromucosal midazolam (Buccolam™), a benzodiazepine, is approved in the EU for the treatment of paediatric patients (aged 3 months to <18 years) with acute, prolonged, convulsive seizures. In clinicalExpand
  • 9
  • 3
Vortioxetine: A Review of Its Use in Major Depressive Disorder
Vortioxetine (Brintellix®) is a serotonin (5-HT) transporter inhibitor that also acts on several 5-HT receptors, such as the 5-HT3 and 5-HT1A receptors. It is approved in the US and the EU for theExpand
  • 28
  • 2